Case Studies
HeartFlow would like to take a moment to recognise sites that are going above and beyond to deliver an outstanding CT service to patients, especially during this COVID pandemic.
We are excited and proud to recognise Royal Stoke University Hospital for their Outstanding CT Service!
Royal Stoke’s cardiac team began the coronavirus pandemic without any CT scanning backlog. However, with the outbreak of the virus, scanning was suspended and the team ended the first wave with a waiting list of 518 patients.
While services such as cancer treatment and 2WW imaging continued during the first wave, Cardiac CT was not initially considered urgent. The cardiothoracic radiologists supported by the imaging management team highlighted the significance of the backlog and risk of potential adverse cardiac events to patients awaiting cardiac CT given the higher mortality for such an event compared to early cancer.
One of the key benefits that Royal Stoke University Hospital has seen from the HeartFlow Analysis has been the ability to minimise time spent in hospitals. This has been invaluable throughout the pandemic, when patients have been apprehensive about attending hospital due to infection risk. With the HeartFlow Analysis, patients have often been able to get a diagnosis in a single visit.
The clarity brought by HeartFlow’s technology has also allowed the Stoke team to take a direct to intervention approach rather than bring patients back for a diagnostic angiogram, with a significant reduction in diagnostic angiograms for moderate coronary artery stenosis reported on CT coronary angiogram.
Royal Stoke University Hospital has gone to great efforts to ensure that patients have been able to receive continued access to the best of cardiac care throughout the COVID pandemic. We, at HeartFlow, are proud to be working with them to enhance heart care for their patients.
“Chest imaging has been the front line of Radiology during COVID and our CT radiographers deserve particular commendation for the work they have done not only for COVID inpatients during the first and second waves, but for simultaneously helping us ramp up to address massive backlogs such as Cardiac CT post the first wave. We have continued to keep the waiting list below 40 since mid-November with all external referrals now open.
With the HeartFlow Analysis, we can often avoid patients undergoing an additional hospital visit and unnecessary invasive procedures to determine a treatment plan. Given the current concerns with social distancing, minimising unnecessary hospitals visits is now more important than ever before. As we restore our diagnostic services to pre-COVID levels and recover from long waiting lists, the HeartFlow Analysis has shown to be a very useful tool in reducing the number of diagnostic tests a patient needs, which in turn improves patient flow through the diagnostic pathways.”
HeartFlow Analysis is consisted of four main functions; FFRCT, Planner, Roadmap, and Plaque. All four functions are cleared for clinical use in the United States, Bahrain, Israel, and United Arab Emirates. Only FFRCT and Planner functions are cleared cleared for clinical use in Europe, United Kingdom, Australia, Canada, and Japan. Please see HeartFlow Analysis Indications for Use and Instructions for Use for more information.
© 2024 HeartFlow, Inc. | HeartFlow and the HeartFlow logo are registered trademarks of HeartFlow, Inc. Additionally, RoadMap is claimed as a trademark of HeartFlow, Inc. www.heartflow.com | 331 E Evelyn Ave, Mountain View, CA 94041
*Required fields
If you would like to request to have the HeartFlow Analysis available at a location near you, please submit your information below with details of the institution. We will share this information with the institution, but it will not guarantee HeartFlow will become available.
*Required fields
オンライン提出フォームから研究助成金を申請してください。
HeartFlow FFRCT 分析は、有資格の臨床医による臨床的に安定した症状のある冠状動脈疾患患者への使用を目的とした個別化された心臓検査です。 HeartFlow Analysis によって提供される情報は、資格のある臨床医が患者の病歴、症状、その他の診断検査、および臨床医の専門的判断と組み合わせて使用することを目的としています。
ハートフロー分析に関する追加の適応情報については、次のサイトをご覧ください。www.heartflow.com/indications.
さらに質問がある場合は、このメッセージを閉じてフォームに記入するか、サポート チームにお電話ください。: 877.478.3569.
The HeartFlow FFRCT Analysis is a personalized cardiac test indicated for use in clinically stable symptomatic patients with coronary artery disease by qualified clinicians. The information provided by the HeartFlow Analysis is intended to be used by qualified clinicians in conjunction with the patient’s history, symptoms, and other diagnostic tests, as well as the clinician’s professional judgement.
For additional indication information about the HeartFlow Analysis, please visit www.heartflow.com/indications.
If you have additional questions, close out of this message to complete our form or call our support team: 877.478.3569.Please use our online submission form on the Clinical Research Page to apply for research grants.
Thank you for your interest!
Executive Vice President and Chief Medical Officer
Campbell brings a wealth of experience to HeartFlow, where he serves as the Chief Medical Officer. Prior to joining HeartFlow, he was the Chief Scientific Officer and Global Head of Research and Development at Cordis Corporation, Johnson & Johnson, where he was responsible for leading investments and research in cardiovascular devices. Prior to Cordis, he was Associate Professor of Medicine at Harvard Medical School and the Harvard-M.I.T. Division of Health Sciences and Technology, and Director of the Cardiac Catheterization and Experimental Cardiovascular Interventional Laboratories at Brigham and Women’s Hospital. He served as Principal Investigator for numerous interventional cardiology device, diagnostic, and pharmacology trials, is the author of numerous journal articles, chapters, and books in the area of coronary artery and other cardiovascular diseases, and was the recipient of research grant awards from the NIH and AHA.
He received his A.B. from Harvard College and his M.D. from Harvard Medical School.